High expression of ETS2 predicts poor prognosis in acute myeloid leukemia and may guide treatment decisions
Open Access
- 19 July 2017
- journal article
- research article
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 15 (1) , 1-9
Abstract
ETS2 is a downstream effector of the RAS/RAF/ERK pathway, which plays a critical role in the development of malignant tumor. However, the clinical impact of ETS2 expression in AML remains unknown. In this study, we evaluated the prognostic significance of ETS2 expression using two relatively large cohorts of AML patients. In the first cohort, compared to low expression of ETS2 (ETS2 low), high expression of ETS2 (ETS2 high) showed significant shorter OS, EFS and RFS in the current treatments including the allogeneic HCT group (n = 72) and the chemotherapy group (n = 100). Notably, among ETS2 high patients, those received allogeneic HCT had longer OS, EFS and RFS than those with chemotherapy alone (allogeneic HCT, n = 39 vs. chemotherapy, n = 47), but treatment modules play insignificant role in the survival of ETS2 low patients (allogeneic HCT, n = 33 vs. chemotherapy, n = 53). Moreover, gene/microRNA expression data provides insights into the biological changes associated with varying ETS2 expression levels in AML. The prognostic value of ETS2 was further validated in the second AML cohort (n = 329). Our results indicate that ETS2 high is a poor prognostic factor in AML and may guide treatment decisions towards allogeneic HCT.Keywords
This publication has 37 references indexed in Scilit:
- Synergistic antitumor activity of triple-regulated oncolytic adenovirus with VSTM1 and daunorubicin in leukemic cellsApoptosis, 2016
- MicroRNA-223 dose levels fine tune proliferation and differentiation in human cord blood progenitors and acute myeloid leukemiaExperimental Hematology, 2015
- Acute Myeloid LeukemiaNew England Journal of Medicine, 2015
- CEBPA-dependent HK3 and KLF5 expression in primary AML and during AML differentiationScientific Reports, 2014
- Clinical Role of microRNAs in Cytogenetically Normal Acute Myeloid Leukemia: miR-155 Upregulation Independently Identifies High-Risk PatientsJournal of Clinical Oncology, 2013
- BAALC and ERG expression levels are associated with outcome and distinct gene and microRNA expression profiles in older patients with de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B studyBlood, 2010
- EVI1 controls proliferation in acute myeloid leukaemia through modulation of miR-1-2British Journal of Cancer, 2010
- Prognostic Importance of MN1 Transcript Levels, and Biologic Insights From MN1-Associated Gene and MicroRNA Expression Signatures in Cytogenetically Normal Acute Myeloid Leukemia: A Cancer and Leukemia Group B StudyJournal of Clinical Oncology, 2009
- The role of the proto-oncogene ETS2 in acute megakaryocytic leukemia biology and therapyLeukemia, 2007
- Overexpression of the ETS-Related Gene, ERG, Predicts a Worse Outcome in Acute Myeloid Leukemia With Normal Karyotype: A Cancer and Leukemia Group B StudyJournal of Clinical Oncology, 2005